Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics to Provide Proctor & Gamble with Drug Targets

NEW YORK, June 11 - Galapagos Genomics has signed on to provide Procter & Gamble Pharmaceuticals with protein drug targets related to osteoporosis, the Mechelen, Belgium, company said today.

 

Under the agreement, Galapagos will provide Proctor & Gamble with protein targets that impact bone formation. Proctor & Gamble will validate the targets and may initiate development of osteoporosis drug candidates based on these targets.

 

Galapagos is to receive option fees, milestone payments, and royalties on sales of any products developed from these targets, the company said, but did not disclose further financial terms of the deal.

 

Galapagos has discovered these targets using PhenoSelect, its gene expression platform which uses arrayed adenoviruses containing human genes to identify and validate targets.

 

This agreement expands on a a previous deal in which Proctor & Gamble agreed to use PhenoSelect to discover targets internally.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.